Related Experiment Video
Updated: Jul 28, 2026

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation
Published on: April 2, 2012
Acyclovir suppression to prevent recurrent genital herpes at delivery
L L Scott1, L M Hollier, D McIntire
1Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA. LLScottMD@aol.com
Objective:
To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection.
Methods:
We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated.
Results:
Six percent of patients treated with acyclovir, and 14% of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102).
Conclusions:
Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.
Related Concept Videos
Sexually Transmitted Infections
Herpes
Chickenpox
Cytomegalovirus Disease
Genital Herpes
Antiviral Nucleoside Inhibitors

